Full-Time

Manager – Automation Engineering

Posted on 11/1/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Milan, Metropolitan City of Milan, Italy

In Person

Category
Electrical Engineering (2)
,
Requirements
  • Advanced knowledge of Distributed Control and Safety Systems and/or PLC applications.
  • Awareness of integrated process control SIMATIC Batch (batch processing).
  • Good demonstratable knowledge of Batch process.
  • Working knowledge of GAMP and GEP.
  • Database administration experience (SQL).
  • Advanced PLC programming skills (eg STL, SCL).
  • High level programming eg: C, C++, VB etc.
  • Completed structured system testing and documentation such as FAT/SAT/OQ protocols.
  • Followed system maintenance programmes.
  • Completed system version upgrades.
  • Capability to install, configure and update Process Control System software (Siemens brand is preferred). Experience of Siemens products (e.g. PCS7).
  • Experience in maintaining and upgrading PLC or DCS control systems.
  • Experience in designing, maintaining and upgrading network infrastructures
  • Soft skills: + Able to form long term relationships with key support groups, QA, engineering, CSV group and senior managers across the site. + Shares ideas and information and acts in a transparent manner + Demonstrates a ‘can do’ approach. + Willing to learn new technologies and their application relevant to the job + Fluent English + Good oral, written and presentation skills essential
  • Master’s degree in engineering, Electrical, Automation or any relevant technical education
  • 7 ÷ 10 years’ experience of PLC based unit operation including graphical interface and data collection
Responsibilities
  • Design and implement Hardware and Software solutions in accordance with Standard Operating Procedures and the Global Automation Policy.
  • Cooperate with the Global Engineering, Internal Manufacturing sites Automation Engineers and IS for the TechOps Automation Roadmap implementation, including the definition of the automation systems interfaces with the IT infrastructure.
  • Support the Site Engineering in the activities of specification and follow up of pharmaceutical plants and equipment using established procedures. These include equipment selection, schematic design, system layout, cost estimation and system documentation.
  • Develop and implement control and automation design based upon cause-and-effect documentation, P&IDs, control narrative and an understanding of the environment.
  • Ensure accuracy and reliability of instrumentation, control and safety systems.
  • Actively identify & pursue process quality, efficiency, and safety improvements, by maintaining cGxP and H&S knowledge applicable to the job and by assessing them against of the “State of the Art” technology.
  • Write and update SOPs and other Process Control System associated documentation as part of the operational lifecycle.
  • Cooperate with the Site Engineering, QA and IS Compliance departments to ensure production continuity and fast problem resolutions and tasks such as audits, CAPAs and validation testing are completed on time successfully and as priority. In particular: + Ensure that deployed systems are available for Manufacturing, maintained, and their qualified status is not compromised. + Cooperate with the Manufacturing team, ensuring all system changes are communicated ahead of time and that production schedule is accounted for. + React quickly to reports of Manufacturing system faults, troubleshoot in collaboration with Manufacturing and the other Engineering disciplines. + Assist in the development software and hardware configuration to remediate system faults or errors, improve efficiency and safety, as requested and in response to CAPA or Error report actions. + Carry out preventative and planned maintenance activities on time and suggests/identifies maintenance requirements where needed. + Carry out system modifications in accordance with the appropriate Change Control procedure.
  • For his/her Area of competence, he/she carries out the operating procedures for the management of his/her activity in compliance with the Principles of the Environmental Policy and the Quality System, applies the relevant guidelines and indications contained in the procedures of the Environmental Management System of his/her competence.
  • Participates in the training and education courses in the field of the Environmental, Safety and Quality Management System and in the training courses on Procedures, Instructions, Manuals and Operating Protocols.
  • He/She is responsible for carrying out his/her activities so that the management of environmental and safety aspects is conducted correctly. Carries out the work activities, in compliance with the directives received, as required by Legislative Decree 81/08 Guarantees compliance with all applicable Laws, Codes, company standards and Procedures relating to his/her area of competence, particularly the requirements of the Jazz Pharmaceuticals Code of Conduct.
Desired Qualifications
  • Experience on the installation, configuration and updating of Process Control System software from major vendors other than Siemens (ABB, Emerson, Rockwell etc.)
  • Experience in the Pharmaceutical Industry
  • Experience of Safety Instrumented Systems
  • Experience of commissioning activities
  • Operational Excellence / Lean manufacturing skills and/or certifications (i.e: Green or Black Belt)

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex achieved $1.1B sales in 2025, growing 9% year-over-year.
  • Recorded $4.3B revenue in 2025, guiding $4.25B-$4.5B for 2026.
  • Renee Gala became CEO August 2025, driving 90% revenue growth.

What critics are saying

  • Epidiolex generics erode 25% of revenue within 12-24 months.
  • Japan Phase 3 Epidiolex failure blocks Asian market entry immediately.
  • Chimerix dordaviprone NDA rejected August 2025, wasting $935M.

What makes Jazz Pharmaceuticals unique

  • Focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Acquired GW Pharmaceuticals in 2021, adding blockbuster Epidiolex for epilepsy.
  • Vyxeos from 2016 Celator acquisition treats acute myeloid leukemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE